Drug-induced liver disease in 2003
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Drug-induced liver disease remains an important topic of concern for all prescribers as well as drug manufacturers. The withdrawal of troglitazone (Rezulin) and bromfenac (Duract) a few years ago remains fresh in the minds of regulatory authorities as well as clinicians and researchers who are focusing renewed attention on ways to better understand mechanisms of injury to predict and avert serious drug-induced liver disease in the future from drugs under development as well as existing agents known to cause liver injury. As in past years, this review describes new and first-time reports of various aspects of drug-induced liver disease for several classes of compounds, including herbal products (such as kava kava), reviews the risk factors seen with antiretroviral and antituberculosis agents among others. It provides a sampling of experimental hepatoprotection studies that may hold the key to treatment and prevention of drug-induced liver disease in the future and discusses the ongoing approaches to be taken to restrict the availability of acetaminophen that have proved successful in reducing the number of overdoses, deaths, and liver transplantations from this drug in the United Kingdom. Given the fact that acetaminophen is the single most important cause of acute liver failure here and abroad, such efforts to limit its use seem appropriate for other nations as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatotoxicity of nucleoside reverse transcriptase inhibitors
(2003) · Seminars in Liver Disease · doi:10.1055/s-2003-39947 · Cited by 62
Cited by
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Katarey, D., & Verma, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s104 · Cited by 331
An Assessment of Statin Safety by Hepatologists
Cohen, D. E., Anania, F. A., & Chalasani, N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.014 · Cited by 269
Drug‐induced liver injury in a Swedish University hospital out‐patient hepatology clinic
DE VALLE, M. B., AV KLINTEBERG, V., ALEM, N., OLSSON, R., & BJÖRNSSON, E. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03117.x · Cited by 179
Vuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200502000-00002 · Cited by 133
Metadata
- Authors
- Pishvaian, A. C., Trope, B. W., & Lewis, J. H.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2004-05
- Volume
- 20
- Issue
- 3
- Pages
- 208-219
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2401723191
- Cited by
- 41
- References
- 1
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-induced liver disease in 2003. https://app.cochat.ai/papers/10.1097/00001574-200405000-00005
- The paper
- Pishvaian, A. C., Trope, B. W., & Lewis, J. H. (2004). Drug-induced liver disease in 2003. Current Opinion in Gastroenterology. https://doi.org/10.1097/00001574-200405000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.